Patents Assigned to Wyeth
  • Enantiomers of O-desmethyl venlafaxine
    Publication number: 20070208084
    Abstract: This invention provides pharmaceutically active enantiomers of the venlafaxine metabolite O-Desmethyl venlafaxine, R(?)-4-[2-(Dimethylamino-1-(1-hydroxycyclo-hexyl)ethyl]phenol or R(?)1-[2-(dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclo-hexanol, and S(+)-1-[2-(Dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclohexanol or S(+)-4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol, or one or more pharmaceutically acceptable salts or salt hydrates thereof, as well as pharmaceutical compositions utilizing these enantiomers and methods of using the enantiomers to treat, inhibit or control central nervous system disorders.
    Type: Application
    Filed: May 1, 2007
    Publication date: September 6, 2007
    Applicant: Wyeth
    Inventors: John Yardley, Andre Asselin
  • Substituted pyrrole-indoles
    Patent number: 7265148
    Abstract: The present invention relates generally to substituted pyrrole-indoles such as substituted pyrrole-indoles, and methods of using them.
    Type: Grant
    Filed: September 23, 2004
    Date of Patent: September 4, 2007
    Assignee: Wyeth
    Inventor: Baihua Hu
  • Mutant proteinase-inhibitors and uses thereof
    Patent number: 7264953
    Abstract: A library of mutants of metastable proteins, such as proteinase inhibitors, can be screened for the specific loss of a wild-type capability to bind an antibody, yielding valuable drug-design information which otherwise is unavailable. By this approach, for example, a mutant proteinase inhibitor can be obtained that has the amino acid sequence of a wild-type protein, or an active fragment thereof, save for the presence of one or more mutations in at least one epitope, thereby altering interaction of the mutant with an anti-proteinase inhibitor antibody.
    Type: Grant
    Filed: July 18, 2002
    Date of Patent: September 4, 2007
    Assignees: American National Red Cross, Wyeth
    Inventors: Daniel A. Lawrence, Natalia Gorlatova, David L. Crandall
  • Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases
    Patent number: 7265152
    Abstract: The present invention relates to novel benzofuran derivatives and analogs, as well as compositions containing the same and to the use thereof for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the hepatitis C virus.
    Type: Grant
    Filed: October 31, 2003
    Date of Patent: September 4, 2007
    Assignees: ViroPharma Incorporated, Wyeth
    Inventors: Ashis K. Saha, Christopher J Burns, Alfred M. Del Vecchio, Thomas R. Bailey, Jason A. Reinhardt, Bheemashankar A. Kulkarni, Thomas H. Faitg, Hao Feng, Susan R. Rippin, Charles W. Blackledge, David J. Rys, Thomas A. Lessen, John Swestock, Yijun Deng, Theodore J. Nitz
  • Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV), proteins encoded by the polynucleic acids, vaccines based on the proteins and/or polynucleic acids, a method of protecting a pig from a PRRSV and a method of detecting a PRRSV
    Patent number: 7264957
    Abstract: The present invention provides a purified preparation containing a polynucleic acid encoding at least one polypeptide selected from the group consisting of proteins encoded by one or more open reading frames (ORF's) of an Iowa strain of porcine reproductive and respiratory syndrome virus (PRRSV), proteins at least 80% but less than 100% homologous with those encoded by one or more of ORF 2, ORF 3, ORF 4 and ORF 5 of an Iowa strain of PRRSV, proteins at least 97% but less than 100% homologous with proteins encoded by one or both of ORF 6 and ORF 7 of an Iowa strain of PRRSV, antigenic regions of such proteins which are at least 5 amino acids in length and which effectively stimulate immunological protection in a porcine host against a subsequent challenge with a PRRSV isolate, and combinations thereof, in which amino acids non-essential for antigenicity may be conservatively substituted.
    Type: Grant
    Filed: July 15, 2003
    Date of Patent: September 4, 2007
    Assignees: Wyeth, Iowa State University Research Foundation, Inc.
    Inventors: Prem S. Paul, Xiang-Jin Meng, Patrick Halbur, Igor Morozov, Melissa A. Lum
  • Sulfonyl Substituted 1H-Indoles as Ligands for the 5-Hydroxytryptamine Receptors
    Publication number: 20070203120
    Abstract: The present invention is directed to compounds of Formula I: which are modulators of the 5-hydroxtryptamine-6 and 5-hydroxytryptamine-2A receptors and which are inhibitors of norepinephrine reuptake. The compounds of the invention, and pharmaceutical composition thereof, are useful in the treatment of disorders related to or associated with the 5-hydroxytryptamine-6 and 5-hydroxtryptamine-2A receptors or with norepinephrine reuptake inhibition.
    Type: Application
    Filed: January 12, 2007
    Publication date: August 30, 2007
    Applicant: Wyeth
    Inventors: Robert E. McDevitt, Yanfang Li, Albert J. Robichaud, Gavin D. Heffernan, Richard D. Coghlan, Ronald C. Bernotas
  • Ion channel modulators
    Publication number: 20070203194
    Abstract: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein cab be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel subtype targets.
    Type: Application
    Filed: March 7, 2005
    Publication date: August 30, 2007
    Applicants: SCION PHARMACEUTICALS, INC., WYETH
    Inventors: Robert Zelle, Vincent Galullo, Christopher Baker, Paul Will, William Frazee
  • Dihydrospiro[dibenzo[a,d][7]annulene-5,4'-imidazol] compounds for the inhibition of beta-secretase
    Publication number: 20070203116
    Abstract: The present invention provides a 10,11-dihydrospiro[dibenzo[a,d][7]annulene-5,4?-imidazol]-5?(1?H)-one compound of formula I Also provided are methods and compositions for the inhibition of ?-secretase (BACE) and the treatment of ?-amyloid deposits and neurofibrillary tangles.
    Type: Application
    Filed: February 23, 2007
    Publication date: August 30, 2007
    Applicant: Wyeth
    Inventors: Dominick Anthony Quagliato, Patrick Michael Andrae, Yi Fan
  • Inhibitors Of PAI-1 For Treatment Of Muscular Conditions
    Publication number: 20070203220
    Abstract: This invention describes novel methods of treating muscle damage, muscle wasting, muscle degeneration, muscle atrophy or reduced rates of muscle repair associated with various conditions such as muscular dystrophy, through the use of small-molecule PAI-1 inhibitors.
    Type: Application
    Filed: February 26, 2007
    Publication date: August 30, 2007
    Applicant: Wyeth
    Inventors: David Crandall, George Vlasuk
  • Neutralizing antibodies against GDF-8 and uses therefor
    Patent number: 7261893
    Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in vitro and/or in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle or bone, or disorders of insulin metabolism.
    Type: Grant
    Filed: October 21, 2003
    Date of Patent: August 28, 2007
    Assignees: Wyeth, Cambridge Antibody Technology Limited
    Inventors: Geertruida M. Veldman, Monique V. Davies, Kening Song, Neil M. Wolfman, Kristie Grove Bridges, Anne Field, Caroline Russell, Viia Valge-Archer
  • Transgenic animal
    Patent number: 7262336
    Abstract: A transgenic rat containing in its genome a nucleotide sequence encoding a Ga subunit protein, which Ga protein subunit is uncoupled from regulation by Regulators of G-Protein Signaling (RGS) proteins, which Gx subunit protein is eventually the dominant-negative G188S mutant of Gax9, which nucleotide sequence is operatively associated with a neuron-specific expression control sequence, wherein the transgenic rat expresses the GA subunit protein in neural cells resulting in extended D-protein coupled receptor signaling mediated by the Ga subunit protein.
    Type: Grant
    Filed: April 24, 2001
    Date of Patent: August 28, 2007
    Assignee: Wyeth
    Inventors: Kathleen Young, David S. Howland, Karen L. Marquis, Sharon Rosenzweig-Lipson, Mark Ian Cockett
  • Circovirus sequences associated with piglet weight loss disease (PWD)
    Patent number: 7261898
    Abstract: The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors; methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided; method for selecting compounds capable of modulating the viral infection is further provided; and pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.
    Type: Grant
    Filed: October 31, 2005
    Date of Patent: August 28, 2007
    Assignee: Wyeth
    Inventors: Andre Jestin, Emmanuel Albina, Pierre Le Cann, Philippe Blanchard, Evelyne Hutet, Claire Arnauld, Catherine Truong, Dominique Mahe, Roland Cariolet, Francois Madec
  • Processes for the convergent synthesis of calicheamicin derivatives
    Publication number: 20070197455
    Abstract: This invention describes processes for the convergent synthesis of calicheamicin derivatives, and similar analogs using bifunctional and trifunctional linker intermediates.
    Type: Application
    Filed: February 20, 2007
    Publication date: August 23, 2007
    Applicant: Wyeth
    Inventors: Justin Keith Moran, Jianxin Gu
  • Pantoprazole multiparticulate formulations
    Publication number: 20070196444
    Abstract: A method of treating gastroesophageal reflux disease (GERD), ulcers of the stomach or duodenum, or Zollinger-Ellison Syndrome in a human, by administering pantoprazole sodium multiparticulates is described. The pantoprazole multiparticulates have a spheroid core of pantoprazole or an enantiomer thereof, or a salt thereof, a surfactant, and a disintegrant; a sub coat which is comprised of hydroxypropyl methylcellulose (hypromellose) and water, an enteric coat on the subcoat, and a final seal coat over the enteric coat, which is composed of hydroxypropyl methylcellulose (hypromellose) and water.
    Type: Application
    Filed: March 30, 2007
    Publication date: August 23, 2007
    Applicant: Wyeth
    Inventors: Sripriya Ramana Rao, Syed Shah, Hanumantharao Tatapudy, Richard Saunders, Mahdi Fawzi, Arwinder Nagi, Shailesh Singh, Sumon Hasan
  • Pantoprazole multiparticulate formulations
    Publication number: 20070196443
    Abstract: Pantoprazole sodium multiparticulates are described which avoid sticking to nasogastric and gastronomy tubes. The pantoprazole multiparticulates have a spheroid core of pantoprazole or an enantiomer thereof, or a salt thereof, a surfactant, and a disintegrant; a sub coat which is comprised of hydroxypropyl methylcellulose(hypromellose) and water, an enteric coat on the sub-coat, and a final seal coat over the enteric coat, which is composed of hydroxypropyl methylcellulose(hypromellose) and water.
    Type: Application
    Filed: March 30, 2007
    Publication date: August 23, 2007
    Applicant: Wyeth
    Inventors: Sripriya Ramana Rao, Syed Shah, Hanumantharao Tatapudy, Richard Saunders, Mahdi Fawzi, Arwinder Nagi, Shailesh Singh, Sumon Hasan
  • Materials and methods for identifying agents that modulate Norrin, Norrin mimetics, and agents identified thereby
    Publication number: 20070196872
    Abstract: The specification discloses materials and methods for screening and identifying reagents, which modulate Norrin activity as it relates to Wnt pathway signaling. Preferably, agents identified thereby modulate bone remodeling and/or lipid levels, and can be Norrin mimetics and Norrin agonists, as well as other agonists and mimetics of the LRP5/Norrin/Frizzled4 complex.
    Type: Application
    Filed: February 6, 2007
    Publication date: August 23, 2007
    Applicant: Wyeth
    Inventors: Frederick Bex, Bheem Bhat
  • Phenylephrine liquid formulations
    Publication number: 20070197661
    Abstract: An oral, aqueous-based, liquid pharmaceutical composition is provided. The composition comprises up to about 45% w/v glycerin and up to about 10% w/v sorbitol wherein the glycerin to sorbitol ratio is about 2:1 to 10:1.
    Type: Application
    Filed: February 9, 2007
    Publication date: August 23, 2007
    Applicant: Wyeth
    Inventors: William Bubnis, Stephanie Shield, Amanda Alley
  • Methods for preparing sulfonamide substituted alcohols and intermediates thereof
    Publication number: 20070197830
    Abstract: Processes for preparing amino alcohols or salts thereof and sulfonamide substituted alcohol compounds are provided. Desirably, the sulfonamide substituted alcohol compounds are heterocyclic sulfonamide trifluoroalkyl-substituted alcohol compounds or phenyl sulfonamide trifluoroalkyl-substituted alcohol compounds.
    Type: Application
    Filed: February 15, 2007
    Publication date: August 23, 2007
    Applicant: Wyeth
    Inventors: Anita Wai-Yin Chan, Jianxin Ren, Mousumi Ghosh, Arkadiy Rubezhov, Panolil Raveendranath, Joseph Zeldis
  • Methods and apparatuses for diagnosing AML and MDS
    Publication number: 20070198198
    Abstract: Methods, systems and equipment for diagnosing or monitoring the progression or treatment of AML or MDS. This invention identifies a plurality of AML or MDS disease genes which are differentially expressed in bone marrow cells of AML or MDS patients as compared to disease-free humans. These AML or MDS disease genes can be used as molecular markers for detecting the presence or absence of AML or MDS. These genes can also be used for the early identification of MDS patients who eventually progress to AML.
    Type: Application
    Filed: April 23, 2007
    Publication date: August 23, 2007
    Applicant: Wyeth
    Inventors: Michael Burczynski, Andrew Dorner, Natalie Twine, William Trepicchio, Jennifer Stover
  • Selective n-sulfonylation of 2-amino flouro-and trifluoroalkyl substituted alcohols
    Publication number: 20070197800
    Abstract: Processes for preparing sulfonamide trifluoroalkyl substituted alcohol compounds are provided. Desirably, the compounds are heterocyclic sulfonamide trifluoroalkyl substituted alcohol compounds or phenyl sulfonamide trifluoroalkyl substituted alcohol compounds.
    Type: Application
    Filed: February 15, 2007
    Publication date: August 23, 2007
    Applicant: Wyeth
    Inventors: Anita Wai-Yin Chan, Jianxin Ren, Mousumi Ghosh, Panolil Raveendranath